<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Small noncleaved cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (SNCCL), a rare <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in adults, is associated with not only a rapid complete response (CR) to chemotherapy but also with the potential to rapidly relapse both systemically and in the <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>We treated 44 assessable adults with two similar protocols, consisting of three sequential chemotherapy combinations and intrathecal prophylaxis with <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>The overall CR rate was 80%; it was 100% in patients with Ann Arbor (AA) stages I-III disease and 57% in those with stage IV disease </plain></SENT>
<SENT sid="3" pm="."><plain>The overall survival (OS) rate at 5 years was 52% </plain></SENT>
<SENT sid="4" pm="."><plain>The overall 5-year freedom from <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> mortality (FTM) rate was 63%; it was 95% for patients with AA stages I-III disease, and 29% for those with stage IV disease </plain></SENT>
<SENT sid="5" pm="."><plain>Stepwise multivariate analysis of factors associated with remission duration and survival indicated that advanced-disease stage and age of 40 years or over were predictors of poor prognosis </plain></SENT>
<SENT sid="6" pm="."><plain>Twelve patients with positive human <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus (HIV) serology were also included in this series </plain></SENT>
<SENT sid="7" pm="."><plain>They had an 83% CR rate and an 83% 5-year FTM, but only a 36% 5-year OS; most <z:hpo ids='HP_0011420'>deaths</z:hpo> were secondary to <z:e sem="disease" ids="C0029118" disease_type="Disease or Syndrome" abbrv="">opportunistic infection</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Histologic subtype (Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>] or non-Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> [NBL]) did not correlate with patient age, site of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> presentation, response to therapy, or survival </plain></SENT>
<SENT sid="9" pm="."><plain>Both protocols achieved comparable results </plain></SENT>
<SENT sid="10" pm="."><plain>The approach used in these protocols is highly effective for patients with early staged disease, regardless of their HIV status; however, better therapy is necessary for those with SNCCL presenting in an advanced stage </plain></SENT>
</text></document>